Business Context and Reporting Period
Jasper Therapeutics, Inc. filed a Form 8-K reporting management changes occurring in September 2023. The report date and earliest event date were September 21, 2023; the new CFO’s employment commenced September 22, 2023, and the related press release was issued September 25, 2023. Jasper is a biotechnology company headquartered in Redwood City, California, with common stock trading under JSPR on Nasdaq.
Key Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating and financial performance metrics.
- Herb Cross was appointed Chief Financial Officer and Corporate Secretary and became the company’s principal financial officer and principal accounting officer.
- Mr. Cross’s initial annualized salary is $460,000, with eligibility for a discretionary annual bonus of up to 45% of base salary and a $100,000 sign-on bonus.
- He received an inducement option to purchase 550,000 shares at an exercise price of $0.78 per share.
- The option vests over four years: 25% on September 22, 2024, and the remainder monthly thereafter, subject to continued service.
Material Changes Versus the Prior Comparable Period
- Jeet Mahal transitioned from Chief Financial Officer and Chief Operating Officer to serving solely as Chief Operating Officer.
- Mr. Mahal no longer serves as Corporate Secretary, principal financial officer, or principal accounting officer.
- Mr. Cross joined the company from Atreca, Inc., where he had served as chief financial officer since February 2019.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance or business outlook. It discloses executive compensation, an equity award, eligibility for the company’s executive severance plan, and a standard indemnification agreement. Mr. Cross’s employment is at will. The filing states that he has no family relationship with any director or executive officer and that no related-party transactions were identified.
The filing also notes that Mr. Cross previously served as an executive of KaloBios Pharmaceuticals, which filed for Chapter 11 bankruptcy in December 2015 and emerged in July 2016. No additional contingencies or unusual financial items are disclosed.
Investor Verification Checklist
- Verify the effective dates of the CFO appointment and Mr. Mahal’s transition.
- Confirm the terms, share count, exercise price, and vesting schedule of the 550,000-share inducement option.
- Assess the expected effect of the new CFO’s salary, bonus opportunity, sign-on payment, equity compensation, and severance eligibility on future expenses and dilution.
- Review subsequent filings for additional management changes, compensation amendments, or equity issuances.
- Consult the company’s financial statements and other SEC filings for liquidity, cash runway, operating performance, debt, and clinical-development risks, which are not addressed in this 8-K.